Pipeline
At Novavax, we leverage our science, our technology and our people to innovate and collaborate in the fight against some of the world’s most significant health challenges.
All of our assets are built using our protein-based nanoparticles and proprietary Matrix-M® adjuvant technology platform.
Starting with our core expertise in infectious disease, we are also investigating other therapeutic areas where we believe our technology could augment and improve upon current therapies.
Scientific rationale, the ability to reach rapid proof-of-concept, unmet medical need and attractiveness to potential partners are what drive our pipeline prioritization.
Vaccines that contain Novavax technology, commercialized in key markets around the world by our partners
* Authorized in select geographies under trade name Nuvaxovid™
** Commercialized by Serum Institute of India. Granted prequalification by the WHO and distributed by UNICEF to endemic countries in Africa.
Early and late-stage vaccines developed by Novavax
* Initial preclinical work funded
** Available for partnership; no current investment
Significant expansion of vaccine pipeline assets that include Novavax technology via partnering approach
* NCT06695117 Granted Fast Track designation in the U.S.